Surfactant protein D (SP-D) alters cellular uptake of particles and nanoparticles

Kendall, Michaela; Ding, Ping; Mackay, Rose-Marie; Deb, Rajib; McKenzie, Zofi; Kendall, Kevin; Madsen, Jens; Clark, Howard

doi:10.3109/17435390.2012.689880

Cited by 57 publications

(65 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The lung-air barrier maintains lung homeostasis (constant internal environment, via gas exchange and pH regulation) and is a critical part of human biological defence mechanisms, with SP-D modulating pro-and anti-inflammatory processes when threatened by toxic challenges. In vivo studies investigating nanoparticle uptake by alveolar macrophages and lung dendritic cells from control and SP-D deficient mice showed decreased uptake of nanoparticles in the SP-D deficient mice compared with wild-type mice, and confirmed an interaction between SP-D and nanoparticles, and subsequent enhanced nanoparticle uptake [23]. Thus, nanoparticles can subvert the natural defence mechanisms of the lung, and may persist in the respiratory tract and translocate into the circulatory system, as indeed has been observed for fine and ultrafine particles over the last few decades.…”

Section: (D) Interactions Of Nanomaterials With the Human Body: Nanosmentioning

confidence: 71%

‘Bio-nano interactions: new tools, insights and impacts’: summary of the Royal Society discussion meeting

Lynch

Feitshans

Kendall

2015

Phil. Trans. R. Soc. B

Self Cite

View full text Add to dashboard Cite

Bio-nano interactions can be defined as the study of interactions between nanoscale entities and biological systems such as, but not limited to, peptides, proteins, lipids, DNA and other biomolecules, cells and cellular receptors and organisms including humans. Studying bio-nano interactions is particularly useful for understanding engineered materials that have at least one dimension in the nanoscale. Such materials may consist of discrete particles or nanostructured surfaces. Much of biology functions at the nanoscale; therefore, our ability to manipulate materials such that they are taken up at the nanoscale, and engage biological machinery in a designed and purposeful manner, opens new vistas for more efficient diagnostics, therapeutics (treatments) and tissue regeneration, so-called nanomedicine. Additionally, this ability of nanomaterials to interact with and be taken up by cells allows nanomaterials to be used as probes and tools to advance our understanding of cellular functioning. Yet, as a new technology, assessment of the safety of nanomaterials, and the applicability of existing regulatory frameworks for nanomaterials must be investigated in parallel with development of novel applications. The Royal Society meeting 'Bio-nano interactions: new tools, insights and impacts' provided an important platform for open dialogue on the current state of knowledge on these issues, bringing together scientists, industry, regulatory and legal experts to concretize existing discourse in science law and policy. This paper summarizes these discussions and the insights that emerged. Background to the meetingThroughout the 21st century, reports about dangers and benefits of using well-established toxins, as well as substances that were previously considered innocuous, have been diligently examined by the Royal Society. The Royal Society has proactively engaged in discussions regarding nanotechnologies since the early 2000s. It was the first major international scientific community to publish its opinion regarding the opportunities and challenges posed by nanotechnologies and nanomaterials for society [1]. As noted in the Royal Society's report in 2004, nanotechnology offers a fresh perspective for scientific understanding of the physical properties of matter. Subsequently, Royal Society journals have published pioneering articles concerning this emerging field, starting with inhalation toxicology and exploring scientific concerns that ultrafine airborne particles might cause harmful effects (figure 1), and the implications of that possible harm when applying nanotechnology in a diverse range of consumer applications [2]. Those findings prompted a pause to reconsider the overwhelmingly positive attitudes regarding the 'nanotechnology revolution'. Thus, although potential dangers from substances used in nanomedicine are unquantified as yet, both the potential benefits of applications and any possible negative implications following their use have consistently been the subject of lively discourse at the Royal Society.On 3...

show abstract

Section: (D) Interactions Of Nanomaterials With the Human Body: Nanosmentioning

confidence: 71%

‘Bio-nano interactions: new tools, insights and impacts’: summary of the Royal Society discussion meeting

Lynch

Feitshans

Kendall

2015

Phil. Trans. R. Soc. B

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lung surfactant phospholipids are also known to coat inhaled particles [21,22], and this can drastically change their toxicity and cellular uptake [23]. In addition, this may lead to agglomeration [24], which might result in agglomerates that are large enough to be digested by macrophages. The binding strength and mode of binding of lung surfactants to the particles largely depends on the surface of the particle [25,26].…”

Section: Surface Modificationsmentioning

confidence: 99%

Medical nanoparticles for next generation drug delivery to the lungs

2014

View full text Add to dashboard Cite

Respiratory diseases are an increasing burden for the ageing population. Although our understanding of these diseases has improved significantly over the past decades, diagnostic and therapeutic options for treating lung diseases, such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and lung cancer, remain limited. Multidisciplinary approaches that bridge the gap between medicinal and materials sciences will likely contribute to promising new therapeutic and diagnostic solutions. One such multidisciplinary approach is the use of nanoparticles as carriers for the delivery of drugs. The advantages of using nanoparticles to deliver drugs include: increased drug concentration at the disease site; minimised drug degradation and loss; ease of creating inhalable formulations; and the possibility of specific cell targeting. This article gives a brief overview on the emerging field of nanocarriers as drug delivery vehicles for the treatment of lung diseases. @ERSpublications This article provides an overview on the emerging field of nanocarriers as drug delivery vehicles for lung therapy

show abstract

“…SP-A has been shown to enhance phagocytosis of IgG-opsonized particles (23) and complement-coated particles (24) and to preferentially bind apoptotic neutrophils, which aides in their removal from the inflamed lung (25,26). SP-D is known to aggregate and aid in the removal of pollen starch granules (27,28), to bind and enhance clearance of genomic DNA and apoptotic cells (29), and to aggregate and remove nanoparticles (30).…”

Section: Roles Of Sp-a/-d In Cell-mediated Immunitymentioning

confidence: 99%

Eosinophil-Associated Lung Diseases. A Cry for Surfactant Proteins A and D Help?

Ledford

Addison

Foster

et al. 2014

Am J Respir Cell Mol Biol

View full text Add to dashboard Cite

Surfactant proteins (SP)-A and SP-D (SP-A/-D) play important roles in numerous eosinophil-dominated diseases, including asthma, allergic bronchopulmonary aspergillosis, and allergic rhinitis. In these settings, SP-A/-D have been shown to modulate eosinophil chemotaxis, inhibit eosinophil mediator release, and mediate macrophage clearance of apoptotic eosinophils. Dysregulation of SP-A/-D function in eosinophil-dominated diseases is also not uncommon. Alterations in serum SP-A/-D levels are associated with disease severity in allergic rhinitis and chronic obstructive pulmonary disease. Furthermore, oligimerization of SP-A/-D, necessary for their proper function, can be perturbed by reactive nitrogen species, which are increased in eosinophilic disease. In this review, we highlight the associations of eosinophilic lung diseases with SP-A and SP-D levels and functions.

show abstract

Surfactant protein D (SP-D) alters cellular uptake of particles and nanoparticles

Cited by 57 publications

References 43 publications

‘Bio-nano interactions: new tools, insights and impacts’: summary of the Royal Society discussion meeting

‘Bio-nano interactions: new tools, insights and impacts’: summary of the Royal Society discussion meeting

Medical nanoparticles for next generation drug delivery to the lungs

Eosinophil-Associated Lung Diseases. A Cry for Surfactant Proteins A and D Help?

Contact Info

Product

Resources

About